ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
- Conditions
- EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 95
- Registration Number
- NCT04245085
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- Conditions
- Non-small Cell Lung CancerStage IVOligometastasis
- Interventions
- Radiation: Stereotactic body radiation therapy (SBRT)Procedure: Surgical resection - definitive local treatment.Radiation: Radical radiotherapy - definitive local treatment.
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 96
- Registration Number
- NCT03965468
- Locations
- 🇮🇹
European Institute of Oncology, Milano, Italy
🇮🇹Istituto Oncologico Veneto - Irccs, Padova, Italy
🇮🇹IRCCS Istituto Nazionale Tumori Regina Elena, Roma, Italy
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
- Conditions
- Breast Cancer Recurrent
- Interventions
- Drug: Standard endocrine therapy
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 405
- Registration Number
- NCT03820830
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇦🇹Medizinische Universität Graz (MUG), Graz, Austria
🇦🇹Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde, Innsbruck, Austria
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
- Conditions
- Pleural Mesothelioma Malignant Advanced
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 401
- Registration Number
- NCT03762018
- Locations
- 🇧🇪
CHU Liege, Liege, Belgium
🇫🇷Le Mans - CHG, Le Mans, France
🇨🇭Kantonsspital Aarau, Aarau, Switzerland
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Conditions
- Estrogen Receptor Positive TumorBreast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 147
- Registration Number
- NCT03644186
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Berard, Lyon, France
🇮🇹Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Recurrent
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 14
- Registration Number
- NCT03445000
- Locations
- 🇳🇱
University Medical Center Maastricht, Maastricht, Netherlands
🇳🇱The Netherlands Cancer Institute Amsterdam, Amsterdam, Netherlands
🇨🇭Hôpital Universitaire de Genève, Genève, Switzerland
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 155
- Registration Number
- NCT03133546
- Locations
- 🇮🇪
St. James Hospital, Dublin, Ireland
🇮🇪Mid Western Cancer Centre, Limerick, Ireland
🇳🇱VU University Medical Centre, Amsterdam, Netherlands
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
- Conditions
- Pleural Mesothelioma Malignant Advanced
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 144
- Registration Number
- NCT02991482
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Winterthur, Winterthur, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
MEtronomic TrEatment Option in Advanced bReast cAncer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT02954055
- Locations
- 🇮🇹
Ospedale di Bolzano Oncologia Medica Via lorenz Bohler 5, Bolzano, Italy
🇮🇹"Antonio Perrino" Division of Medical Oncology Strada Statale 7 APPIA, Brindisi, Italy
🇮🇹IRST IRCCS Division of medical oncology Via Maroncelli 40, Meldola, Italy
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 124
- Registration Number
- NCT02536742
- Locations
- 🇧🇪
CHU Liege, Liège, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇮🇹Azienda USL4 Prato, Prato, Italy